Critical questions in metastatic castration-resistant prostate cancer: Integrating emerging clinical evidence and guideline recommendations

American Journal of Experimental and Clinical Research

View Publication Info
 
 
Field Value
 
Title Critical questions in metastatic castration-resistant prostate cancer: Integrating emerging clinical evidence and guideline recommendations
 
Creator Ali, Mohamed; Consultant Medical Oncologist Department of Medical Oncology National Cancer Institute Cairo, Egypt P.O.Box 4009.
Yousif, Abubakr; Consultant Clinical Oncologist National Cancer Institute Cairo, Egypt P.O.Box 4009.
Ahmed, Yasar AA; Physician Oncologist Oncology Center Sligo Regional Hospital, Ireland
 
Subject Medicine; urology
Prostate cancer, metastasis, castration-resistant, treatment, guidelines

 
Description Metastatic castration-resistant prostate cancer (CRPC) typically confers a poor prognosis, however, novel advances in treatment options, as well as biomarkers for monitoring disease response and progression, have recently helped improve survival rates. Additionally, new guidelines provide some direction on incorporating these new treatments but some confusion still exists among clinicians about best methods for initiating treatment and the optimal sequencing of agents to prolong survival. In this article, we review the literature and answer some frequently asked questions about treating men with metastatic CRPC, including choosing a first-line treatment, monitoring treatment response, and proceeding to additional lines of therapy.
 
Publisher American Journal of Experimental & Clinical Research
 
Contributor
 
Date 2016-01-07
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Article

 
Format application/pdf
 
Identifier http://journals.sfu.ca/ajecr/index.php/ajecr/article/view/56
 
Source American Journal of Experimental and Clinical Research; Vol 3, No 1 (2016); 138-140
2330-9245
2330-9237
 
Language eng
 
Relation http://journals.sfu.ca/ajecr/index.php/ajecr/article/view/56/146
 
Rights Authors who publish with the American Journal of Experimental and Clinical Resaerch (AJECR) agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2016 Simon Fraser University Library